Study on the clinical significance of Saireito in patients with hypertensive nephropathy

Study on the clinical significance of Saireito in patients with hypertensive nephropathy - Clinical effects of Saireito in patients with hypertensive nephropathy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011825

Enrollment

Registered

2013-09-20

Start date

2011-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertensive nephropathy

Interventions

Saireito (EK-114, Kracie Pharma, Ltd., Tokyo, Japan) at 8.1g was additionally administered for 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with persistent hypertension and with microalbuminuria ranging 20 to 400 mg/gCr

Exclusion criteria

Exclusion criteria: * in pregnancy and lactating * contraindicative or impossible to use for some reason for Saireito * treated with oral corticosteroids or immunosuppressant therapy * interstitial pneumonitis * definite diabetes mellitus * marked renal impairment (eGFR = or < 30 ml/min) * primary renal disease * secondary renal disease * serious CHF * serious arrythmia * within 6 months after AMI * within 6 months after cerebrovascular disease

Design outcomes

Primary

Measure	Time frame
Decrease in microalbuminuria	—

Countries

Japan

Contacts

Public ContactFumihiko Hinoshita

National Center for Global Health and Medicine Hospital Department of Nephrology

fhinoshi@hosp.ncgm.go.jp03-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026